You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Lebanon, New Hampshire 03756

  • Melanoma (Skin)


RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.

Study summary:

OBJECTIVES: Primary - Determine the dose-limiting toxicity and the maximum tolerated dose of autologous dendritic cells pulsed with autologous tumor cell lysate in patients with stage III or IV melanoma. - Determine the safety and tolerability of this therapy in these patients. Secondary - Determine the immune response, in terms of the type and degree of T-cell proliferation and delayed-type hypersensitivity responses, in patients treated with this therapy. OUTLINE: This is a dose-escalation, pilot study. Patients undergo leukapheresis for the collection of peripheral blood mononuclear cells (PBMC) on days -9, 19, and 47. Autologous dendritic cells (DC) are prepared from autologous PBMC exposed to sargramostim (GM-CSF), interleukin-4, and tumor necrosis factor alpha and pulsed with autologous tumor cell lysate. Patients receive autologous tumor cell lysate-pulsed DC IV over 5-10 minutes on days 0, 28, and 56. Cohorts of 3-6 patients receive escalating doses of autologous tumor cell lysate-pulsed DC until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 33% of all patients experience dose-limiting toxicity. Patients are followed at day 84 and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 3-20 patients will be accrued for this study within 3-20 months.


DISEASE CHARACTERISTICS: - Histologically confirmed melanoma - Stage III (lymph node or in-transit metastases) or IV (systemic metastases) disease - Patients with relapsed disease OR who failed prior immunotherapy or chemotherapy are eligible (but trial not restricted to relapsed or refractory disease) - Tumor tissue available and properly stored for lysate preparation PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 60-100% Life expectancy - At least 12 weeks Hematopoietic - Absolute neutrophil count ≥ 1,000/mm^3 - Platelet count ≥ 75,000/mm^3 Hepatic - AST ≤ 2 times upper limit of normal (ULN) (3 times ULN for liver metastases) - Bilirubin ≤ 2 times ULN - Hepatitis B surface antigen negative - Hepatitis C negative Renal - Creatinine ≤ 2.0 times ULN Immunologic - No active infection - No history of autoimmune disease, including any of the following: - Inflammatory bowel disease - Systemic lupus erythematosus - Scleroderma - Rheumatoid arthritis - Multiple sclerosis - No allergy to aminoglycosides or streptomycin - HIV negative Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No significant comorbid illness - No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics - At least 10 days since prior immunotherapy Chemotherapy - See Disease Characteristics Endocrine therapy - At least 6 weeks since prior steroid therapy - No concurrent corticosteroids Radiotherapy - At least 10 days since prior radiotherapy - No concurrent radiotherapy Surgery - At least 10 days since prior surgery - Prior diagnostic or palliative surgery allowed provided the patient has fully recovered Other - No concurrent immunosuppressive or potentially immunosuppressive therapy



Primary Contact:

Study Chair
Christopher P. Tretter, MD
Norris Cotton Cancer Center

Backup Contact:


Location Contact:

Lebanon, New Hampshire 03756
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.